3 results about "Slow Virus Diseases" patented technology

The application belongs to the technical field of biological medicine, and discloses a spinal cord injury treatment drug based on a LINC00311 / miR-4318 / MYLK regulation axis and an application thereof, and aims to solve the technical problems of poor targeting and large side effects of the existing anti-inflammatory treatment of spinal cord injury. The effective component of the drug is an inhibitor of LINC00311, the inhibitor is selected from one or more of shRNA, siRNA, antisense oligonucleotide and CRISPRi system, can target the specific nucleotide sequence of LINC00311, and can be used in combination with miR-4318 mimic, and is administered by intrathecal injection, slow virus carrier delivery and the like. The in-vitro experiment proves that the inhibitor can significantly inhibit the release of TNF-alpha, IL-1beta, IL-6 and other pro-inflammatory factors by microglia cells; the in-vivo experiment shows that it can significantly improve the BBB motor function score of spinal cord injury rats, and reduce spinal cord tissue edema and necrosis. The application first discloses the mechanism of the LINC00311 / miR-4318 / MYLK ceRNA regulation axis in spinal cord injury, has the advantages of novel target, significant effect and high transformation potential, and provides a new scheme for the clinical treatment of spinal cord injury.

The application relates to the technical field of the cross of microfluidic technology, chemical synthesis and biomedicine, and discloses a method for preparing EGFR CAR-NK cells based on polypeptide gel droplet confined transfection technology and application, which comprises the following steps: (1) preparing collagen-mimic-peptide-modified alginate; (2) constructing a confined transfection system: adopting a droplet microfluidic chip, wrapping NK cells and slow virus carrying an EGFR CAR gene in the collagen-mimic-peptide-modified alginate droplet prepared in the step (1), and obtaining a gel droplet after gelation of the droplet; and (3) confined transfection and cell culture. The method can significantly reduce the dosage of slow virus and cell toxicity, greatly improve the transfection success rate of the CAR gene, the survival rate and functional activity of the NK cells, and finally obtain EGFR CAR-NK cell products with higher purity and stronger target killing capacity.